BACKGROUND: Neuroendocrine tumours very rarely occur in the biliary tract; information about them is limited. AIMS: To present the clinical characteristics and prognosis of curatively resected biliary neuroendocrine tumours. METHODS: Review of medical records dated between 2000 and 2010 of 20 patients from three medical centres with biliary neuroendocrine tumour based on curative resection. RESULTS: Based on the World Health Organization 2010 classification, five and one patients had neuroendocrine tumour grades 1 and 2, seven had neuroendocrine carcinoma, and seven were diagnosed with mixed adenoneuroendocrine carcinoma. The locations were the following: seven in the gallbladder, four in the extrahepatic bile duct, and nine in the ampulla of Vater. Lymph node and hepatic metastases were noted in 11 and 4 patients, respectively. Fourteen patients experienced recurrence; most had recurrence in the liver. Patients with neuroendocrine tumour grade 1 had a lower rate of recurrence compared to others (p=0.001). The median disease-free and overall survival times were 5.8 (0.4-53.6) and 13.7 (1.9-102.1) months for all four subtypes. However, the median disease free and overall survival rates of neuroendocrine tumours were significantly longer than those of neuroendocrine carcinomas or mixed adenoneuroendocrine carcinoma. CONCLUSIONS: Patients with biliary neuroendocrine tumour showed extremely different clinical outcomes according to histopathologic subtypes by World Health Organization 2010 classification. Copyright Â
BACKGROUND:Neuroendocrine tumours very rarely occur in the biliary tract; information about them is limited. AIMS: To present the clinical characteristics and prognosis of curatively resected biliary neuroendocrine tumours. METHODS: Review of medical records dated between 2000 and 2010 of 20 patients from three medical centres with biliary neuroendocrine tumour based on curative resection. RESULTS: Based on the World Health Organization 2010 classification, five and one patients had neuroendocrine tumour grades 1 and 2, seven had neuroendocrine carcinoma, and seven were diagnosed with mixed adenoneuroendocrine carcinoma. The locations were the following: seven in the gallbladder, four in the extrahepatic bile duct, and nine in the ampulla of Vater. Lymph node and hepatic metastases were noted in 11 and 4 patients, respectively. Fourteen patients experienced recurrence; most had recurrence in the liver. Patients with neuroendocrine tumour grade 1 had a lower rate of recurrence compared to others (p=0.001). The median disease-free and overall survival times were 5.8 (0.4-53.6) and 13.7 (1.9-102.1) months for all four subtypes. However, the median disease free and overall survival rates of neuroendocrine tumours were significantly longer than those of neuroendocrine carcinomas or mixed adenoneuroendocrine carcinoma. CONCLUSIONS:Patients with biliary neuroendocrine tumour showed extremely different clinical outcomes according to histopathologic subtypes by World Health Organization 2010 classification. Copyright Â
Authors: James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola Journal: Cancer Genomics Proteomics Date: 2019 Sep-Oct Impact factor: 4.069
Authors: Nickos Michalopoulos; Theodossis S Papavramidis; Georgia Karayannopoulou; Ioannis Pliakos; Spiros T Papavramidis; Ioannis Kanellos Journal: Pathol Oncol Res Date: 2014-06-11 Impact factor: 3.201